These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32448079)

  • 1. Infliximab treatment in refractory vascular Behcet's disease: A single-center experience.
    Kehribar DY; Ozgen M
    Vascular; 2020 Dec; 28(6):829-833. PubMed ID: 32448079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab therapy in parenchymal neuro-Behçet's disease: A single-center experience.
    Yalcin Kehribar D; Gunaydin S; Ozgen M
    Int J Rheum Dis; 2021 Oct; 24(10):1302-1307. PubMed ID: 34427044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients.
    Desbois AC; Biard L; Addimanda O; Lambert M; Hachulla E; Launay D; Ackermann F; Pérard L; Hot A; Maurier F; Mausservey C; Bernard F; Noel N; Alric L; Mirault T; Cohen F; Boussouar S; Resche-Rigon M; Cacoub P; Saadoun D
    Clin Immunol; 2018 Dec; 197():54-59. PubMed ID: 30125675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
    Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of TNF inhibitors in patients with Behçet's disease: Retrospective study from eastern Turkey.
    Bektaş M; Özer MD; Oğuz E
    Clin Immunol; 2024 Jul; 264():110239. PubMed ID: 38734038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab.
    Zou J; Ji DN; Cai JF; Guan JL; Bao ZJ
    Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature.
    Aksoy A; Yazici A; Omma A; Cefle A; Onen F; Tasdemir U; Ergun T; Direskeneli H; Alibaz-Oner F
    Int J Rheum Dis; 2020 Feb; 23(2):256-261. PubMed ID: 31976619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease.
    Capella MJ; Foster CS
    Ocul Immunol Inflamm; 2012 Jun; 20(3):198-202. PubMed ID: 22486265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
    Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
    Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
    [No Abstract]   [Full Text] [Related]  

  • 13. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
    Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
    Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.
    Barešić M; Reihl M; Habek M; Vukojević N; Anić B
    Rheumatol Int; 2018 Jul; 38(7):1301-1306. PubMed ID: 29777341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
    Horiguchi N; Kamoi K; Horie S; Iwasaki Y; Kurozumi-Karube H; Takase H; Ohno-Matsui K
    Sci Rep; 2020 Dec; 10(1):22227. PubMed ID: 33335139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for vascular involvement in Behçet's syndrome.
    Hatemi G; Tukek NB; Esatoglu SN; Ozguler Y; Taflan SS; Uygunoglu U; Melikoglu M; Ugurlu S; Fresko I; Siva A; Kutlubay Z; Yurdakul S; Yazici H; Hamuryudan V
    Clin Immunol; 2023 Aug; 253():109682. PubMed ID: 37385325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab in the treatment of Budd-Chiari syndrome in Behçet's disease.
    Santos LB; Rigueira J; Vilas AP
    Reumatismo; 2019 Oct; 71(3):163-165. PubMed ID: 31649380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.
    Ohno S; Umebayashi I; Matsukawa M; Goto T; Yano T
    Arthritis Res Ther; 2019 Jan; 21(1):2. PubMed ID: 30611312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of vascular Behçet's disease.
    Alibaz-Oner F; Direskeneli H
    Int J Rheum Dis; 2019 Jan; 22 Suppl 1():105-108. PubMed ID: 29665281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
    Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
    Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.